<DOC>
	<DOC>NCT02668367</DOC>
	<brief_summary>This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1. Healthy men and women; 2. Age 18 to 60 years, inclusive; 3. Weight â‰¥ 50 kg and Body Mass Index (BMI) of 19 to 32, inclusive; 4. Female subjects must be of nonchildbearing potential; 5. Male subjects must agree to use a double barrier method of birth control; 6. Signed informed consent form (ICF) prior to study procedures. 1. Current or recent (within 14 days of Day 0) bacterial or viral infection; 2. Positive results at screening for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody; 3. Clinically significant abnormalities noted on ECG; 4. Safety laboratory abnormalities; 5. Regular use of medications, prescription or nonprescription; 6. Poor vein access or fear of venipuncture or sight of blood; 7. Major surgery, significant recent injury or trauma within 30 days; 8. Received an investigational drug or vaccine within 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Viral Diseases</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae Infections</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Aviragen Therapeutics, Inc.</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>